| Field | Specification |
|---|---|
| Target | |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Conjugate | |
| Purification | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes hypermethylated in cancer 1 protein (gene hic1.L) in african clawed frog samples.
In the African clawed frog Xenopus laevis, hic1.L encodes a homolog of Hypermethylated in cancer 1 (HIC1), a zinc-finger transcriptional repressor of the BTB/POZ family. Xenopus is used to study how HIC1 family repressors act during embryonic development.
| Target | Hypermethylated in cancer 1 protein (gene hic1.L; UniProt A0A1L8HD87, Xenopus laevis) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | African clawed frog |
| Form | Liquid |
| Formulation | 50% glycerol; 0.9% NaCl; 0.2% Na2HPO4; 0.02% NaN3 |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Reactivity Notes
The supplier lists reactivity with african clawed frog. UniProt places hypermethylated in cancer 1 protein in the nucleus.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
